Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Knowledge Hub

Vaccinating children against pneumonia also reduced ear infections and saved healthcare costs

Over a four-year period following the introduction of PCV-10 in Finland, purchases of antimicrobials that are recommended for the treatment of acute otitis media (middle-ear infection) for children born during these years fell by nearly 18%, compared to pre-vaccine years, and the rate of surgeries to place ear tubes for severe cases fell 15%. Although it is considered a mild disease, acute otitis media caused by pneumococcus is 1,000 times more common in young children than invasive pneumococcal disease, such as pneumonia or meningitis, and thus the public health impact of the vaccine in reducing otitis media cases and in saving health care costs is considerable.

Full Citation:
Palmu AA, Rinta-Kokko H, Nohynek H et al.. 2018. Impact of national ten-valent pneumococcal conjugate vaccine program on reducing antimicrobial use and tympanostomy tube placements in Finland. Pediatric Infectious Disease Journal. 37(1).

Title of Article: Impact of national ten-valent pneumococcal conjugate vaccine program on reducing antimicrobial use and tympanostomy tube placements in Finland

Author(s): Palmu AA, Rinta-Kokko H, Nohynek H et al.

Publication Year: 2018

Publication Name: Pediatric Infectious Disease Journal

Publication Volume: 37(1)

Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/29088026/

DOI (Digital Object Identifier): 10.1097/INF.0000000000001810

Topics: Health

Disease Vaccines: Pneumococcal disease/PCV/PPSV

Countries: Finland

WHO Regions: Europe